Molecular pathology and potential therapeutic targets in soft-tissue sarcoma

Expert Review of Anticancer Therapy

Volumn 8, Issue 6, 2008, Pages 939-948

  Todd, Radha ^a   Lunec, John ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Molecular pathology; Soft tissue sarcoma; Therapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CANCER VACCINE; CD135 ANTIGEN; CETUXIMAB; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DACARBAZINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCOPROTEIN P; IFOSFAMIDE; IMATINIB; MERLIN; MITOMYCIN C; NEUROFIBROMIN; ONYX 015; PLACEBO; PROTEIN MDM2; PROTEIN P53; PROTEIN RET; RETINOBLASTOMA PROTEIN; RETROVIRUS VECTOR; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; TANESPIMYCIN; TRASTUZUMAB; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ALVEOLAR SOFT PART SARCOMA; AMPUTATION; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER GENE THERAPY; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CHONDROSARCOMA; CHROMOSOME TRANSLOCATION; CLEAR CELL SARCOMA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DERMATOFIBROMA; DERMATOFIBROSARCOMA PROTUBERANS; DESMOPLASTIC SMALL ROUND CELL TUMOR; DRUG RESPONSE; DRUG SELECTIVITY; DRUG TARGETING; ENDOMETRIUM SARCOMA; EWING SARCOMA; EXTERNAL BEAM RADIOTHERAPY; FIBROSARCOMA; GENE DELETION; GENE MUTATION; HEREDITY; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; LUNG TUMOR; MONOTHERAPY; MULTIDRUG RESISTANCE; MYXOSARCOMA; NERVE SHEATH TUMOR; NONHUMAN; REVIEW; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; DRUG DELIVERY SYSTEM; GENE TRANSLOCATION; GENETICS; METASTASIS; SARCOMA; SOFT TISSUE TUMOR;

ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASM METASTASIS; SARCOMA; SOFT TISSUE NEOPLASMS; TRANSLOCATION, GENETIC;

EID: 47249085698     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.6.939     Document Type: Review

References (80)

1. CancerStats Monograph 2004. Toms JR (Ed.). Cancer Research UK, London, UK (2004).
2. World Health Organisation Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and Bone. Fletcher CDM, Unni KK, Mertens F (Eds). IARC Press, Lyon, France (2002).
3. Trojani M, Contesso G, Coindre JM et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int. J. Cancer 33, 37-42 (1984).
4. Coindre JM, Trojani M, Contesso G et al. Reproducibility of a histopathologic grading system for adult soft tissue sarcoma. Cancer 58(2), 306-309 (1986).
5. Guillou L, Coindre JM, Bonichon F et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J. Clin. Oncol. 15(1), 350-362 (1997).
6. Delaney TF, Yang JC, Glatstein E. Adjuvant therapy for adult patients with soft tissue sarcomas. Oncology 5, 105-118 (1991).
7. Clasby R, Tilling K, Smith MA, Fletcher CDM. Variable management of soft tissue sarcomas: regional audit with implications for specialist care. Br. J. Surg. 84, 1692-1696 (1997).
8. Rosenberg SA, Tepper J, Glatstein E et al. The treatment of soft tissue sarcomas of the extremities. prospective randomised evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann. Surg. 196, 305-315 (1982).
9. Suit HD, Mankin HJ, Wodd WC et al. Treatment of the patient with stage M0 soft tissue sarcoma. J. Clin. Oncol. 6(5), 854-862 (1988).
10. Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 350, 1647-1654 (1997).
11. Gasco M, Crook T. p53 family members and chemoresistance in cancer: what we know and what we need to know. Drug Resist. Updat. 6, 323-328 (2003).
12. Coley HM, Verrill MW, Gregson SE, Odell DE, Fisher C, Judson IR. Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma. Eur. J. Cancer 36(7), 881-888 (2000).
13. Mocellin S, Rossi CR, Brandes A, Nitti D. Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches. Cancer Treat. Rev. 32, 9-27 (2006).
14. Malkin D, Li FP, Strong LC et al. Germline p53 mutations in a Familial syndrome of breast cancer, sarcomas and other neoplasms. Science, 250, 1233-1238 (1990).
15. Li FP, Fraumeni JF. Soft tissue sarcomas, breast cancer and other neoplasms. A familial syndrome? Ann. Intern. Med. 71, 747-752 (1969).
16. Li FP, Fraumeni JF, Mulvihill JJ et al. A cancer family syndrome in twenty foar kindreds. Cancer Res. 48, 5358-5362 (1988).
17. Sanchez-Garcia I. Consequences of chromosomal abormalities in tumor development. Ann. Rev. Genet. 31, 429-453 (1997).
18. Hogendoorn PCW, Collin F, Daugaard S et al. Changing concepts in the pethological basis of soft tissue and bone sarcoma treatment. Eur. J. Cancer 40, 1644-1654 (2004).
19. Guillou L, Benhattar J, Bonichon F et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J. Clin. Oncol. 22(20), 4040-4050 (2004).
20. Nilsson M, Meza-Zepeda LA, Mertens F, Forus A, Myidebost O, Mandahl N. Amplification of chromosome 1 sequences in lipomatous tumours and other sarcomas. Int. J. Cancer 109, 363-169 (2004).
21. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-Function mutations of c-kit in human gastrointestinal stromal tumours. Science 279(5350), 577-580 (1988).
22. Nakanishi H, Myoui A, Ochi T, Aozasa K. P-glycoprotein expression in soft-tissue sarcomas. J. Cancer Res. Clin. Oncol. 123(6), 352-356 (1997).
23. Serra M, Scotlandi K, Manara MC et al. Evaluation of P-glycoprotein expression in soft tissue sarcomas of the extremities. Cytotechnology 19(3), 253-256 (1996).
24. Hoffmann J, Schmidt-Peter P, Hansch W et al. Anticancer drug sensitivity and expression of multidrug resistance markers in early passage human sarcomas. Clin. Cancer Res. 5, 2198-2204 (1999).
25. Jimenez RE, Zalupski MM, Frank JJ, Du W, Ryan JR, Lucas DR. Multidrug resistance phenotype in high grade soft tissue sarcomas. Cancer 86(6), 976-981 (1999).
26. Nielsen TO, West RB, Linn SC et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 359, 1301-1307 (2002).
27. Ren B, Yu YP, Jing L et al. Gene expression analysis of human soft tissue leiomyosarcomas. Hum. Pathol. 34(6), 549-558 (2003).
28. Allander SV, Illei PB, Chen Y et al. Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2 and ELF3 with epithelial differentiation. Am. J. Pathol. 161(5), 1587-1595 (2002).
29. Nuciforo PG, Pellegrini C, Fasani R et al. Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma. Hum. Pathol. 34(7), 639-645 (2003).
30. Barbashini V, Benevenia J, Aviv H et al. Oncoproteins and proliferation markers in synovial sarcomas: a dinicopathological study of 19 cases. J. Res. Clin. Oncol. 128(11), 610-616 (2002).
31. Olsen RJ, Lydiatt WM, Koepsell SA et al. C-erb-B2 (HER2/neu) expression in synovial sarcoma of the head and neck. Head Neck 27(10), 883-892 (2005).
32. Sapi Z, Papai Z, Hruska A, Antal I, Bodo M, Orosz Z. Her-2 oncogene amplification, chromosome 17 and DNA ploidy status in synovial sarcoma. Pathol. Oncol. Res. 11(3), 133-138 (2005).
33. Thomas DG, Giordano TJ, Sanders D et al. Expression of receptor tyrosine kinases, epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer 103(4), 830-838 (2005).
34. Terry J, Lubieniecka JM, Kwan W, Liu S, Nielsen TO. Hsp 90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models. Clin. Cancer Res. 11(15), 5631-5638 (2005).
35. Hollstein M, Rice K, Greenblatt MS et al. Database of p53 gene somatic mutations in human tumours and cell lines. Nucleic Acids Res. 22, 3551-3555 (1994).
36. Yoo J, Lee HK, Kang CS, Park WS, Lee JY, Shim SI. p53 gene mutations and p53 protein expression in human soft tissue sarcomas. Arch. Pathol. Lab. Med. 121(4), 395-399 (1997).
37. Lowe SW, Bodis S, McClatchey A et al. p53 status and the efficacy of cancer therapy in vivo. Science 266, 807-810 (1994).
38. Schmitt CA, Lowe SW. Apoptosis is critical for drug response in vivo. Drug Resist. Updat. 4, 132-134 (2001).
39. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between camcer genetics and chemotherapy. Cell 108, 153-164 (2002).
40. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutations on resistance of cultured cells to chemotherapy. Oncogene 18, 477-485 (1999).
41. Geisler S, Lonning PE, Aas T et al. Influence of TP53 gene alterations and c-erb-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 61, 2505-2512 (2001).
42. Rahko E, Blanco G, Soini Y, Bloigu R, Jukkola A. A mutant TP53 gene status is associated with a poor prognosis and anthracycline resistance in breast cancer. Eur. J. Cancer 39, 447-453 (2003).
43. Wu X, Bayle H, Olson D, Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7, 1126-1132 (1993).
44. Bartel F, Meye A, Wurl P et al. Amplification of the MDM2 gene, but not expression of splice variants of MDM2 RNA, is associated with prognosis in soft tissue sarcoma. Int. J. Cancer 95, 168-175 (2001).
45. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acid Res. 26(15), 3453-3459 (1998).
46. INK4a/CDKN2A tumor suppressor and its relatives. Biochim. Biophys. Acta 1378(2), 115-177 (1998).
47. Silva J, DominguezG, Silva JM et al. Analysis of genetic and epigenetic processes that influence p14ARF expression in breast cancer. Oncogene 20, 4586-4590 (2001).
48. ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol, 11, 159-168 (2001).
49. ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92, 713-723 (1998).
50. ARF with Mdm2 inhibits ubiquitin ligase activity of MDM2 for tumour supressor p53. EMBO J. 18, 22-27 (1999).
51. Weber JD, Koo M-L, Bothner B et al. Cooperative signals governing ARF-Mdm2 interaction and nucleolar localisation of the complex. Mol. Cell Biol. 20, 2517-2528 (2000).
52. Lopez-Guerrero JA, Pellin A, Noguera R, Carda C, Llombart-Bosch A. Molecular analysis of the 9p21 locus and p53 genes in Ewing family tumours. Lab. Invest. 81(6), 803-814 (2001).
53. Tsuchiya T, Sekine K, Hinohara S, Namiki T, Nobori T, Kaneko Y. Analysis of the p16INK4, P14ARF, P15, TP53, and MDM2 genes and their prognostic ?indications in osteosarcoma and Ewing sarcoma. Cancer Genet. Cytogenet. 120, 91-98 (2000).
54. Orlow I, Dtobnjak M, Zhang ZF et al. Alterations of INK4A and INK4B genes in adult soft tissue sarcomas: effect on survival. J. Natl Cancer Inst. 91(1), 73-79 (1999).
55. Roth JA, Nguyen D, Lawerence DD et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat. Med. 2, 985-991 (1996).
56. Hupp TR. Regulation of p53 protein function through alterations in protein-following pathways. Cell. Mol. Life Sci. 55, 88-95 (1999).
57. Bykov VJ, Selivanova G, Wiman KG. Sniall molecules that reactivate mutant p53. Eur. J. Cancer 39, 1828-1834 (2003).
58. Roth J, Lenz-Bauer C, Contente A et al. Reactivation of mutant p53 by a one-hybrid adaptor protein. Cancer Res. 63, 3904-3908 (2003).
59. Makower D, Rozenblit A, Kaufman H et al. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumours with correlative p53 studies. Clin. Cancer Res. 9, 693-702 (2003).
60. Galanis E, Okuno SH, Nascimiento AG et al. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Therapy 12(5), 437-445 (2005).
61. Vassilev LT, Vu BT, Graves B et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004).
62. Tovar C, Rosinski J, Filipovic Z et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc. Natl Acad. Sci. USA 7(103), 1659-1660 (2006).
63. Debeic-Rychter M, Dumez H, Judson I et al. Use of c-KITPDGFRA mutational analysis to predict the clinical response to imarinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer 10, 689-695 (2004).
64. Verweij J, van Oosterom A, Blay JY et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: results from an EORTC Soft Tissue and Bone Sarcoma Group Phase II study. Eur. J. Cancer 39, 2006-2011 (2003).
65. Prenen H, Cools J, Mentens N et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumour mutants refractory to imatinib mesylate. Clin. Cancer Res. 12(8), 2622-2627 (2006).
66. Demetri GD, van Oosterom A, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced ga!trointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368 (9544), 1329-1338 (2006).
67. Zucman J, Melot T, Desmaze C et al. Combinatorial generation of variable fusion proteins in the ewing family of tumours. EMBO J. 12, 4481-4487 (1993).
68. Turc-Carel C, Aurias A, Mugrieret F et al. Chromosomes in Ewings Sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet. Cytogenet. 32(2), 229-238 (1988).
69. Kaneko Y, Yoshida K, Handa M et al. Fusion of an ETS-family gene, E1AF to EWS by t(17;22) (q12;q12) chromosome translocation in an undiferentiated sarcoma of infancy. Genes Chromosomes Cancer 15, 115-121 (1996).
70. Peter M, Couturier J, Pacquement H et al. A new member of the ETS family fused to EWS in Ewing tumours. Oncogene 14, 1159-1164 (1997).
71. Antonescu CR, Tschernyavsky SJ, Woodruff JM, Jungbluth AA, Brennan M, Ladanyi M. Detection of EWS-ATF1 and MITF-M transcripts and histopathological and ultrastructural analysis of 12 cases. J. Mol. Diagn. 4(1), 44-52 (2002).
72. Labelle Y, Zucman J, Stenman G et al. Oncogeneic conversion of a novel orphan nuclear receptor by chromosome translocation. Hum. Mol. Genet. 4, 2219-2226 (1995).
73. Ladanyi M, Gerald W. Fusion of the EWS and ET1 genes in the desmoplastic small round cell tumour. Cancer Res. 54, 2837-2840 (1994).
74. Waters BL, Panagopoulos I, Allen EF. Genetic characterization of angiomatoid fibrous histiocytoma identifies fusion of the FUS and ATF-1 genes induced by the chromosomal translocation involving bands 12q13 and 16p11. Cancer Genet. Cytogenet. 121, 109-116 (2000).
75. Raddaoui E, Donner LR, Panagopoulos I. Fusion of the FUS and ATF-1 genes in a large, deep-seated angiomatoid fibrous histiocytoma. Diagn. Mol. Pathol. 11, 157-162 (2002).
76. Ladanyi M, Lui MY, Antonescu CR et al. The der(17)t(X;17)(p11;q25)of human alveolar soft part sarcoma fuses the TFE transcription factor gene to ASPL, a novel gene at 17q25. Oncogene 20, 48-57 (2001).
77. Fitzgerald JC, Scherr AM, Barr FG. Structural analysis of PAX7 rearrangements in alveolar rhadbomyosarcoma. Cancer Genet. Cytogenet. 117(1), 37-40 (2000).
78. Sirvent N, Maire G, Pedctour F. Genetics of dermatofibrosarcoma protuberans family of tumours: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer 37, 1-19 (2003).
79. Knezevich SR, McFadden DE, Tao W, Linm JF, Sorensen PH. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nature Genetics 18, 184-187 (1998).
80. Koontz JI, Soreng AL, Nucci M et al. Frequent hisign of the JAZF1 and JJAZ1 genes in endometrial stromal tumours. Proc. Natl. Acad. Sci. USA 98(11), 6348-6353 (2001).